Skip to content
Capsul News Capsul News
4 min read

Trial Tuesday: Idiopathic Pulmonary Fibrosis Waits On Its Groundhog Day

Bristol Myers Squibb is expected to report Phase III data for its LPA1 antagonist admilparant in IPF in the fourth quarter of 2026. The readout is being watched as a signal for other drugs in the same class and for a broader IPF pipeline.

Top-hatted handlers gather onstage at Gobbler's Knob for the Punxsutawney Phil Groundhog Day ceremony.
In IPF, one readout could signal whether it's an early spring for a whole class of drugs. Photo by Steve Wrzeszczynski on Unsplash.
Share Share Share Email

Read next

Milestone Monday: Count the Events, Not the Paperwork

Watchdog Wednesday: The User Fee Deal That Skipped Dessert